Ascendis Pharma A/S financial data

Symbol
ASND on Nasdaq
Location
Hellerup
Fiscal year end
31 December
Latest financial report
20-F - Q4 2024 - 12 Feb 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,689,487 shares 5.2%

Income Statement

Label TTM Value / Value Unit Change %
Research And Development Expense €73,544,000 EUR -34%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets €1,179,495,000 EUR 43%
Liabilities €1,285,201,000 EUR 32%